Novelix Pharmaceuticals Ltd
₹ 41.0
-2.38%
26 Sep
- close price
About
Incorporated in 1994, Novelix Pharmaceuticals Ltd trades in Pharmaceuticals and related products , shares, and securities[1]
Key Points
- Market Cap ₹ 59.4 Cr.
- Current Price ₹ 41.0
- High / Low ₹ 52.8 / 21.9
- Stock P/E 104
- Book Value ₹ 17.6
- Dividend Yield 0.00 %
- ROCE 0.96 %
- ROE 0.64 %
- Face Value ₹ 10.0
Pros
- Company is almost debt free.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding has decreased over last quarter: -13.8%
- Company has a low return on equity of 0.11% over last 3 years.
- Company has high debtors of 216 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5.76 | 1.46 | 1.01 | 3.65 | 3.12 | 3.61 | 1.50 | 1.31 | 1.14 | 1.92 | 4.22 | 30.72 | 52.47 | |
| 4.86 | 0.98 | 0.58 | 3.45 | 2.64 | 3.41 | 1.32 | 4.50 | 2.86 | 1.92 | 4.47 | 30.58 | 51.71 | |
| Operating Profit | 0.90 | 0.48 | 0.43 | 0.20 | 0.48 | 0.20 | 0.18 | -3.19 | -1.72 | 0.00 | -0.25 | 0.14 | 0.76 |
| OPM % | 15.62% | 32.88% | 42.57% | 5.48% | 15.38% | 5.54% | 12.00% | -243.51% | -150.88% | 0.00% | -5.92% | 0.46% | 1.45% |
| 0.00 | 0.00 | 0.04 | 0.13 | -0.04 | 0.11 | 0.00 | 0.00 | 0.23 | 0.00 | 0.31 | 0.02 | -0.08 | |
| Interest | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.29 | 0.40 | 0.34 | 0.12 | 0.15 | 0.12 | 0.08 | 0.08 | 0.07 | 0.06 | 0.04 | 0.04 | 0.03 |
| Profit before tax | 0.60 | 0.08 | 0.13 | 0.21 | 0.29 | 0.19 | 0.10 | -3.27 | -1.56 | -0.06 | 0.02 | 0.12 | 0.65 |
| Tax % | 31.67% | 87.50% | 30.77% | 23.81% | 34.48% | -31.58% | 20.00% | 0.00% | -0.64% | 0.00% | 50.00% | 33.33% | |
| 0.42 | 0.02 | 0.10 | 0.15 | 0.18 | 0.25 | 0.09 | -3.27 | -1.56 | -0.06 | 0.01 | 0.08 | 0.57 | |
| EPS in Rs | 0.52 | 0.02 | 0.12 | 0.19 | 0.22 | 0.31 | 0.11 | -4.04 | -1.93 | -0.07 | 0.01 | 0.08 | 0.55 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 36% |
| 5 Years: | 83% |
| 3 Years: | 200% |
| TTM: | 1728% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 15% |
| 5 Years: | -2% |
| 3 Years: | 27% |
| TTM: | 435% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 61% |
| 3 Years: | 61% |
| 1 Year: | 87% |
| Return on Equity | |
|---|---|
| 10 Years: | -4% |
| 5 Years: | -11% |
| 3 Years: | 0% |
| Last Year: | 1% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 8.10 | 8.10 | 8.10 | 8.10 | 8.10 | 8.10 | 8.10 | 8.10 | 8.10 | 8.10 | 8.10 | 9.95 |
| Reserves | 3.35 | 3.24 | 3.34 | 3.49 | 3.72 | 3.91 | 3.97 | 0.70 | -0.86 | -0.90 | -0.75 | 7.59 |
| 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 0.45 | 0.26 | 0.19 | 0.15 | 0.44 | 0.18 | 0.02 | 0.02 | 0.01 | 0.06 | 0.01 | 9.67 | |
| Total Liabilities | 11.94 | 11.60 | 11.63 | 11.74 | 12.26 | 12.19 | 12.09 | 8.82 | 7.25 | 7.26 | 7.36 | 27.21 |
| 1.17 | 0.75 | 0.55 | 0.59 | 0.61 | 0.37 | 0.31 | 0.22 | 1.96 | 0.17 | 0.12 | 0.19 | |
| CWIP | 0.00 | 0.00 | 0.08 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.32 | 1.40 | 3.01 | 1.84 | 2.92 | 2.72 | 3.53 | 3.64 | 0.59 | 2.78 | 3.06 | 0.04 |
| 10.45 | 9.45 | 7.99 | 9.31 | 8.73 | 9.10 | 8.25 | 4.96 | 4.70 | 4.31 | 4.18 | 26.98 | |
| Total Assets | 11.94 | 11.60 | 11.63 | 11.74 | 12.26 | 12.19 | 12.09 | 8.82 | 7.25 | 7.26 | 7.36 | 27.21 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0.03 | -0.43 | 2.03 | -1.07 | 1.08 | -0.44 | 1.21 | 0.58 | 0.59 | -2.41 | -0.34 | -13.68 | |
| 0.50 | -0.25 | -1.76 | 0.97 | -1.27 | 0.45 | -0.42 | 0.21 | 0.28 | 0.08 | 0.19 | 2.93 | |
| -0.03 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 11.32 | |
| Net Cash Flow | 0.50 | -0.69 | 0.27 | -0.10 | -0.19 | 0.01 | 0.79 | 0.78 | 0.87 | -2.33 | -0.16 | 0.56 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 53.86 | 30.00 | 3.61 | 40.00 | 129.86 | 216.37 | 19.47 | 25.08 | 32.02 | 36.12 | 0.86 | 215.53 |
| Inventory Days | 27.55 | 0.00 | 28.18 | 19.03 | 13.18 | 38.93 | 89.46 | 238.83 | 221.70 | 113.11 | 10.37 | |
| Days Payable | 4.30 | 0.00 | 53.63 | 13.18 | 4.87 | 3.58 | 0.00 | 13.52 | 0.00 | 114.80 | ||
| Cash Conversion Cycle | 77.11 | 30.00 | 3.61 | 68.18 | 95.26 | 216.37 | 53.53 | 110.96 | 270.84 | 244.30 | 113.98 | 111.10 |
| Working Capital Days | 570.95 | 2,225.00 | 2,583.91 | 863.00 | 932.39 | 858.41 | 1,710.63 | 819.16 | 646.75 | 743.31 | 345.97 | 197.11 |
| ROCE % | 5.40% | 0.70% | 0.79% | 0.69% | 2.82% | 0.67% | 0.83% | -31.34% | -19.20% | -0.83% | 0.27% | 0.96% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Change in Directorate
21 Sep - AGM approved appointments: Mr Gattu and Ms Mayuri effective 14 Aug 2025; secretarial auditor Apr 2025–Mar 2030.
-
Shareholders Meeting- AGM
21 Sep - AGM voting results (19 Sep 2025): nine resolutions passed; consolidated scrutinizer report; record date 12 Sep 2025.
- Shareholders Meeting- AGM 21 Sep
-
Shareholder Meeting / Postal Ballot-Outcome of AGM
19 Sep - 31st AGM on 19 Sep 2025: adopted FY2024-25 financials; approved borrowing limit, charges, s186/s185 approvals; appointed directors.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
28 Aug - Submission of News paper publication of Notice of AGM & e-voting information.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Business Overview:[1][2][3]
NPL is a recent entrant in the life sciences research and pharmaceutical intermediates business. In FY24, the company altered its objectives to expand into the pharmaceutical bulk drug segment and healthcare research, analytics, and technology. Currently, it is engaged in pharmaceutical research and the production and trading of bulk drugs (Active Pharmaceutical Ingredients) as well as key starting materials and intermediates.